Reduced early response to SARS‐CoV2 vaccination in people with type 1 and type 2 diabetes, a 6 months follow‐up study: The CoVaDiab study I

Diabetes mellitus worsens the prognosis of SARS‐CoV‐2 infection, and vaccination has been the major tool for reducing the risk of hospitalisation, and mortality.

[1]  Jingxuan Xu,et al.  Serum Neutralizing Antibody Titers 12 Months After COVID-19 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Antinori,et al.  Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. , 2022, Diabetes.

[3]  P. Pozzilli,et al.  Third dose of COVID‐19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy , 2022, Diabetes/metabolism research and reviews.

[4]  M. Zhao,et al.  Clinical Variables Correlate with Serum Neutralizing Antibody Titers after COVID-19 mRNA Vaccination in an Adult, US-based Population , 2022, medRxiv.

[5]  N. Goswami,et al.  Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study , 2021, medRxiv.

[6]  J. V. Van Praet,et al.  Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents. , 2021, The Journal of infectious diseases.

[7]  M. Gui,et al.  Humoral and cellular immune response to severe acute respiratory syndrome coronavirus‐2 vaccination in haemodialysis and kidney transplant patients , 2021, Nephrology.

[8]  G. Paolisso,et al.  Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study , 2021, Diabetes, obesity & metabolism.

[9]  R. Buzzetti,et al.  Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes , 2021, Diabetes Research and Clinical Practice.

[10]  K. Sugiyama,et al.  Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine , 2021, medRxiv.

[11]  A. Huppert,et al.  BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.

[12]  S. Takeda,et al.  The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan , 2021, medRxiv.

[13]  M. Vidali,et al.  Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine , 2021, Diagnostics.

[14]  G. Muscogiuri,et al.  The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism , 2021, Endocrine.

[15]  A. Lenzi,et al.  Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine , 2021, Diabetes/metabolism research and reviews.

[16]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[17]  A. Bhalla,et al.  Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[18]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[19]  A. Davalli,et al.  Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study , 2020, Diabetologia.

[20]  R. Holman,et al.  Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II) , 2020, Cardiovascular Diabetology.

[21]  F. Agrò,et al.  Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I) , 2020, Diabetes Research and Clinical Practice.

[22]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[23]  I. Hung,et al.  Vaccination in patients with chronic kidney disease—Review of current recommendations and recent advances , 2020, Nephrology.

[24]  R. Buzzetti,et al.  Covid‐19 and diabetes mellitus: unveiling the interaction of two pandemics , 2020, Diabetes/metabolism research and reviews.

[25]  N. Curtis,et al.  Factors That Influence the Immune Response to Vaccination , 2019, Clinical Microbiology Reviews.